Global Radiopharmaceuticals Market Size and Forecast 2023-2032|Siemens Healthcare Private Limited, Bayer, GE Healthcare, Novartis AG, Cardinal Health,

The Radiopharmaceuticals Global Market Report 2023 by The Business Research Company, provides radiopharmaceuticals market overview across 60+ geographies in the seven regions – Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa for the 27 major global industries. The report covers a ten-year historic period – 2010-2021, and a ten-year forecast period – 2023-2032.

Learn More On The Radiopharmaceuticals Market:

https://www.thebusinessresearchcompany.com/report/radiopharmaceutical-global-market-report

According to The Business Research Company’s Radiopharmaceuticals Global Market Report 2023, the global radiopharmaceuticals market size will grow from $5.9 billion in 2022 to $6.17 billion in 2023 at a compound annual growth rate (CAGR) of 4.7%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market size of global radiopharmaceuticals is expected to grow from $8.25 billion in 2027 at a CAGR of 7.5%.

The increasing prevalence of cancer and cardiovascular diseases is projected to drive the demand for the radiopharmaceuticals market. Radiopharmaceuticals are emerging as a safe and effective therapeutic option over conventional medicines. Radiopharmaceuticals provide an upper hand to radiologists to treat cancer and cardiovascular diseases due to their benefits such as targeted therapy. Cancer is considered to be the second major cause of death, with around 1 in 6 deaths due to cancer worldwide.

Get A Free Sample Of The Report (Includes Graphs And Tables):

https://www.thebusinessresearchcompany.com/sample.aspx?id=3471&type=smp

The radiopharmaceuticals market is segmented:

1) By Type: Diagnostic, Therapeutic, Other Types

2) By Application: Oncology, Cardiology, Gastroenterology, Neuroendocrinnology, Neurology, Nephrology, Other Applications

3) By End User: Hospitals, Ambulatory Surgical Centers, Diagnostic Centers, Cancer Research Institutes, and Other End Users

Research collaborations and partnerships are gaining significant popularity in the radiopharmaceuticals market over recent years. Major companies operating in the radiopharmaceuticals market are collaborating with other industry players to conduct R&D activities to expand their business. For instance, in March 2020, Debiopharm, a Switzerland-based biopharmaceutical company, signed a research agreement with 3B Pharmaceuticals (3BP), a Germany-based biotechnology firm, to develop the Debio 0228 radioligand program, targeting CAIX (Carbonic Anhydrase 9) enzyme to fight the progression of cancer.

The radiopharmaceuticals market report table of contents includes:

1. Radiopharmaceuticals Market Executive Summary

2. Table of Contents

3. List of Figures

4. List of Tables

5. Report Structure

26. Radiopharmaceuticals Market Pipeline Analysis

27. Key Mergers And Acquisitions In The Radiopharmaceuticals Market

28. Global Radiopharmaceuticals Market Opportunities And Strategies

29. Radiopharmaceuticals Market, Conclusions And Recommendations

30. Appendix

Top Major Players: